e-Newsletter – May 2023
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Search
Search results
What’s in store: a sneak peek at the Retina UK conferences
The latest podcast from Retina UK.
SB-007 update: dose-expansion portion of SpliceBio’s phase 1/2 trial underway with first participant dosed at Oxford
SpliceBio has begun the dose-expansion portion of their phase 1/2 clinical trial of SB-007, a dual adeno-associated viral vector gene therapy for Stargardt disease.
Therapy development updates
There are many ongoing clinical and laboratory studies around the world, exploring innovative approaches to treating inherited sight loss.
Belite Bio announces promising phase 3 results for Stargardt disease
The latest research news from Retina UK.
Gene therapy treatment Luxturna accepted for use in Scotland
Retina UK is delighted that the Scottish Medicines Consortium (SMC) has accepted the gene therapy Luxturna (voretigene neparvovec) for ongoing use by the NHS in Scotland.
Sepul Bio begins clinical trial of ultevursen for USH2A-associated RP
Sepul Bio begins clinical trial of ultevursen for USH2A-associated RP
Mirugen – Unlocking the Power of Retina Regeneration
Mirugen – Unlocking the Power of Retina Regeneration
Retinal transplantation studies
Several groups around the world are investigating the use of retinal transplantation in the treatment of inherited retinal diseases.
Research news roundup – innovation in 2022
Despite the knock-on effects of the pandemic, there’s been a lot going on this year in the world of research! Here are snapshots of a few stories that have appeared in the Research News section of our website in 2022.